7/102 sources · 2 publishersUpdated Nov 10, 14:05 UTC
Coya Therapeutics posts steep Q3 revenue drop, loss and Fast Track designation
Coya Therapeutics reported third‑quarter 2026 revenue of $234.13 K, down 93.4% from a year earlier, and a net loss of $10.62 M, 401.8% higher YoY. The company finished patient enrollment for its COYA‑302 ALS Phase 2/3 trial, which the FDA has granted Fast Track status. GAAP earnings per share were a loss of $0.45, missing consensus by $0.11.
Why it matters
The firm said its cash balance should sustain operations into the second half of 2027, giving it runway to advance the trial. The earnings miss and large loss may pressure the share price in the near term.
Key facts
- 1Q3 2026 revenue was $234.13K, a 93.4% decline year‑over‑year. tradingview.com
- 2Net loss for the quarter was $10.62M, a 401.8% increase year‑over‑year. tradingview.com
- 3The company completed enrollment in the COYA‑302 ALS Phase 2/3 study. tradingview.com
- 4The FDA granted Fast Track designation to the COYA‑302 trial. tradingview.com
- 5Cash resources are expected to last through the second half of 2027. tradingview.com
- 6GAAP EPS was a loss of $0.45, missing consensus by $0.11. seekingalpha.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.